Protocol Ledger

NCT06522997 · Phase II · COMPLETED

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

Interventional Phase II clinical trial protocol NCT06522997 sponsored by Bayer in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-08 Enrollment: 1,222 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06522997
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,222 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06522997
Protocol FieldVerified Registry Value
NCT IdentifierNCT06522997
Consolidated Lead SponsorBayer
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,222 participants (ACTUAL)
Registered Start Date2024-08-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06522997
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
Vanderbilt University Medical CenterNashville, TNOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI